now connected to the targeted reaction. Waste reactions consume any diverted waste 122 metabolites. In the case of reversible reactions, two irreversible reactions are created with 123 different waste metabolites, and alpha is applied to both reactions. This is the drug 124 perturbed model. The drug perturbed model is sent to the optimization module 125 "optimizeProb" with the algorithm set to "fba". Growth inhibition is calculated with the 126 unperturbed and perturbed growth fluxes. After each dose for combinations or single 127 agents, we reset to the original model to implement the next perturbation. 128
Drug effects on a targeted metabolic reaction were implemented in the genome-scale 129 model either by limiting the target flux (FBA-res) or limiting the amount of mass converted 130 from substrate to product by diverting metabolic mass to a waste reaction (FBA-div) . 131
Inhibition values Inhib = 1 -f treat /f wt , where f wt and f treat are the simulated biomass flux rates for 132 untreated and drug treated bacteria. In both cases the MOMA quadratic programming 133 algorithm for simulating perturbed biological networks was implemented to find the change in 134 biomass flux. The IC50 value for a reaction describes the amount by which reaction flux 135 must be reduced to inhibit growth by 50%. For FBA-res, flux is directly restricted by a scalar 136 drug concentration, and so the IC50 is the scalar that achieves a 50% growth inhibiting flux 137 restriction. For FBA-div, flux is diverted to a waste reaction, and so the IC50 is the value 138 that achieves 50% growth inhibiting flux diversion. First, a central perturbation of α cent (where 139 α cent =1+[Inhibitor]/K i and for simplicity K i =1) was found for each target enzyme using a 140 bisection search to yield half the inhibition level of a full FBA gene deletion (for enzymes  141 showing no deletion phenotype, we used α=5,000,000 since this value reproduced synthetic 142 lethal interactions in [12] . Simulated response curves were then generated for each enzyme, 143 with five concentrations centered on this α cent using 3x dilution steps of inhibitor 144 concentration (α-1), covering a ~100x dynamic range (Fig 2A) . For each pair of agents, we 145 then generated dose matrices by simulating combined inhibitors at all pairs of those 146 concentrations ( Fig 2B) . 147
Complete analysis methods are provided as an R-project package, which includes 148 the metabolic network matrix, the analysis code, and all supporting data files. Complete 149 simulation results are also provided in S1 Table.  150 allow fuller use of the dose-responsiveness of inhibitors. The maximum inhibition max(I) and 156 50% crossing concentration IC50 was measured for each target, and if max(I)<0.5, IC50 was 157 set to the top concentration. 158
Synergy was then determined for each dose matrix using either an effect difference 159 max(ΔI) or "shift index" SI50, compared to the single agents ( Fig 2B) . The combination data 160 I XY (blue point) are compared to the corresponding single agent response values I X ,I Y (green 161 points), and max(ΔI) = max{I XY -max(I X ,I Y ) }, shows the Gaddum "best single agent" 162 expectation [32] . All combination points were considered, with the largest difference across 163 the matrix recorded as the score. Positive max(ΔI) values correspond to synergy (more 164 effect than the better single agent at comparable doses). For dose shifting, the matrix 165 diagonal (blue area) is compared to the two single agent curves (green areas). The 166 combination's 50% inhibitory crossing point along the diagonal has single agent component 167 concentrations C50 X and C50 Y , which are compared to the single agent 50% inhibitory 168 concentrations IC50 X and IC50 Y , to calculate SI50 = max(C50 X /IC50 X , C50 Y /IC50 Y ). This 169 SI50 indicates whether the combination shows synergistic (SI50<1) or antagonistic (SI50>1) 170 dose shifting, relative to the Gaddum response surface. We also calculated a standard 171 Loewe combination index CI50 = C X /IC50 X + C Y /IC50 Y , which measures synergy relative to 172 Loewe dose additivity [33] , which is used to determine whether a combination outperforms a 173 "drug-with-itself" sham combination (CI50=1 for dose-additive). All scores for simulated and 174 experimental combinations are listed in S1 Table.  175 Simulated epistasis was classified ( Fig 2C and D) based on the max(I) values for a 176 combination and its single agents. If a combination's max(I) < 0.05 or max(ΔI) < 0.05, we 177 set epistasis to non-interaction "None", corresponding to a Gaddum "best single agent" 178 interaction model. Epistasis was then set to potentiation "Pot" if single agent max(I) >= 0.5 179 for both agents, synthetic lethal "SL" if max(I) < 0.5 for both agents, or partial synthetic lethal 180 "PSL" otherwise. To account for higher noise levels in experimental combinations, we used 181 the same classification scheme, except that epistasis=None was called when max(I) < 0.25 182 or max(ΔI) < 0.25 for a combination. Epistasis calls are recorded in S1 Table.  183 tested in an 8x8 well 2d drug-gradient matrix in a 96 well plate, in addition to the drug matrix 188 the plate also contained gradients for each of the sing drugs as well as negative and positive 189 controls. For both the drug matrix and the single drug gradients the highest drug 190 concentrations were 4 times above the minimal inhibitory concentration (MIC). The plates 191 were inoculated with a 96 pin replicator and incubated 18-20 hours at 37º C. After 192 incubation, OD600 was read using a BioTek H1 plate reader. Each plate was produced in 193 five replicates. Raw data are presented in S4 Table, and response scores are in S1 Table. 194 195 196 Results 197
Flux balance analysis frameworks for modeling drug inhibition 198
Extensive networks of microbial metabolism have been constructed that link together 199 thousands of species-specific metabolic reactions mined from the literature and online 200 databases [34] . Simulating the behavior of microbial metabolism requires not only the 201 stoichiometry captured by such networks, but also detailed kinetic parameters which are 202 unknown for most reactions -even for well-studied microbes like E. coli. FBA addresses this 203 limitation by replacing those parameters with linear fluxes through all the metabolic 204 reactions, and using linear programming to derive steady-state flux values optimized on an 205 objective function constructed from experimental abundances of nucleotides, amino acids 206 and of anabolic metabolites [15, 16, 35] . FBA models optimize steady-state production of 207 these essential building blocks, enforcing consistency with limits imposed by the network's 208 connectivity, flux limits and the conservation of mass between reactions. 209 FBA models have been used to successfully predict the effects of genetic knockouts 210 [15, 17] .
In FBA, under steady state, a system of j=1…N reactions between i=1…M 211 metabolites should satisfy ∑ j s ij v j = 0, where v j are the reaction velocities and s ij are 212 stoichiometric coefficients that account for reaction affinities and connectivity. FBA models 213 solve for the v j that maximize simulated flux through the objective function, constrained by 214 this mass conservation requirement and any v j,min <v j <v j,max limits. To model gene essentiality 215 using the standard knockout "FBA-ko" approach, the target enzyme's reaction rate is set to 216 v j =0, after which the model is re-optimized with a linear programming algorithm to maximize 217 the objective function ( Fig 1B and S1 Fig) . Growth is represented by a biomass reaction 218 which integrates the outputs from many metabolic pathways. A refinement to FBA applies 219 "minimization of metabolic adjustment" (MOMA) [36] , which requires the re-optimized 220 reaction coefficients to minimize their distance from the unperturbed values, rather than 221 seeking the maximum objective function flux consistent with the applied constraints. MOMA 222 has been applied to E. coli and yeast metabolic networks and can successfully predict 223 phenotypic responses to single [36] and double knockout experiments [18] . 224
Extending FBA to drug perturbations, we consider two approaches: our previous 225 "FBA-res" directly restricts the target flux while our new "FBA-div" diverts flux to non-226 productive waste. FBA-res reduces the velocity v j through a targeted reaction by a scalar 227 factor α ( Fig 1C and S1 Fig ) . Thus, instead of FBA's v j =0 constraint, we set v j !v j /α and re-228 optimize the reaction fluxes. FBA-div modeling scales down the target's stoichiometric 229 affinity, rather than its maximum reaction rate (Figure1D and S1 Fig) . Specifically, FBA-div 230 inhibits an enzyme by setting s ij !s ij /α, for metabolites targeted by the inhibitor, before re-231 optimizing to the objective function. To conserve mass, we introduce transport reaction, 232 s i(N+1) , with compensating stoichiometric coefficients s i(N+1) =1-∑ j s ij /α that divert excess 233 substrate to an infinite waste sink. We use standard FBA linear programming to solve the 234 optimization problem in conjunction with our FBA-div methodology. In contrast to 235 this waste diversion prevents other enzymes from increasing their reaction rates in response 236 to target flux restriction. This usually predicts greater biomass reductions than FBA-res for 237 the same level of target flux inhibition. 238 239 240
Simulating drug epistatic interactions 241
To evaluate these approaches, we simulated combination effects using standard 242 FBA-ko, FBA-res and FBA-div, applied to the iAF1260 model of Escherichia coli metabolism 243
[30]. To explore mechanistic patterns, we chose 50 enzymes to cover synthetic lethal 244 synergies and antagonisms found using FBA-ko [12] and sample key pathways in bacterial 245 metabolism (S2 Table) . Inhibition of each target was simulated at 5 "drug" concentrations 246 using FBA-res and FBA-div, in each case estimating inhibition by the flux through the growth 247 reaction in perturbed and unperturbed states (Methods and S1 Fig) . We used the same 248 methodology to generate combination response matrices across all 25 pairings of single 249 drug concentrations. To score the simulation results, we used metrics of single agent and 250 combined inhibitor responses, based on maximum inhibition levels or on 50% inhibitory 251 concentrations IC50 (Fig 2A and B) , and focused our analysis on the maximum effect max(I) 252 and synergy score max(ΔI). We also classified simulated interactions into four epistasis 253 types, based on the dose matrix response shapes ( Fig 2C and D) . These analyses were 254 performed for all 1225 possible pairwise combinations of our 50 targets (S1 Table) . 255
The single agent responses were very similar between methodologies, but 256 combinations differed greatly (Fig 3 and S2-S4 Figs) . Both FBA-res and FBA-div single 257 agent activities were consistent with FBA knockouts (R~1, Fig 4) . Moreover, even the IC50 258 concentrations showed a strong quantitative correlation (R=0.98, Fig 5) . For combinations 259 ( Fig 4B) , all three approaches mostly generated non-interacting pairs, with max(I) reflecting 260 the more effective single agent's, and no epistasis. However, there is a clear increase in the 261 number and variety of interactions between FBA-ko, FBA-res, and FBA-div. While FBA-ko 262 synergies were restricted to synthetic lethal (SL) epistasis, some partial synthetic lethal 263 (PSL) appeared in FBA-res, and a large number of potentiation (Pot) synergies were added 264 with FBA-div. 265
Arranging the results by target pathway reveals informative patterns . First, we located our iAF1260 targets on the iJR904 [37] pathway maps, and then 267 assigned gene identities with reference to KEGG [34] . Pathways were then represented 268 using concise descriptors listed in S2 Table. All three simulation approaches show active 269 single agents clustered in pathways essential for E. coli growth in rich media (glycolysis, 270 citrate cycle, folate and murein biosynthesis, and certain amino acid pathways), and the 271 responses for any particular enzyme are more or less uniform within each such pathway. 272
Combination effects within pathways and interactions across pathways were mostly 273 consistent across targets in each pathway even though they vary substantially between the 274 different simulation methodologies. Specifically, FBA-ko (Fig 3 and S2 Fig) with active targets, especially between serial targets in the same pathway. Interestingly, the 287 level of Pot synergy varied, with the strongest between serial targets in the same pathway 288 (eg, in folate, murein, and amino-Lys). Cases where specific enzymes in a pathway stand 289 out can be explained. For example in murein biosynthesis, there is strong FBA-res synergy 290 between ALAR in amino-Ala with MCT1App and MPTG but the synergy is much weaker with 291 UAGCVT (Fig 3 and S4 Fig) . This can be understood as an extension of serial target 292 synergy, because multiple alanine moieties dependent upon ALAR are added by MCT1App 293 to its substrate, but below UAGCVT in the pathway. Another example is the especially 294 strong interaction of SDPTA in amino/Lys with targets in Energy/citrate. A by-product of 295 SDPTA is alpha-ketoglutarate (akg), a key metabolite in the citrate cycle. Table) . Results are 308 reported in S4 Table, with combination response matrices displayed in S5 Fig. Calculated  309 response and synergy scores are integrated with the model scores (S1 Table) . 310
Given the variety of pharmacodynamic effects that influence single agent potencies, 311 we did not expect and also did not find strong agreement between the simulated and 312 experimentally observed single agent max(I) or IC50 values (S1 Table) . Aside from the 313 clinical antibiotics, there are very few well characterized probes with selective activity on 314 single metabolic targets, so it is not surprising that half of the compounds showed no activity 315 against E. coli proliferation (S1 Table) . The antibiotics showed some agreement with the 316 FBA simulations in terms of Max(I) and IC50, but only in a qualitative sense. 317
For combinations, however, flux-diverted FBA was able to model the strong antibiotic 318 synergies that target serial enzymes within a pathway ( Fig 6A) . FBA-div predicts the large 319 potency shifts seen for both Sulfx+Trimp and Ampcl+Aztrm, while FBA-res and FBA-ko do 320 not ( Fig 6B and S1 Table) . The experiments also found a number of moderate synergies 321 (Fig 7) , most of which involve inhibitors of targets just upstream of the same two pathways 322 (eg, Ampcl or Aztrm combined with Fosfm or Cyser). Only a hint of the antibiotic synergy is 323 detected for those probes, however, most likely due to less-specific enzyme targeting. 324
Combination effects were absent, as expected, for those probes showing no single agent 325 activity and thus not likely to have any relevant activity on the ascribed target. Finally, there 326 was one experimental antagonism (Ampcl+Sulfx), that was not predicted by any of the FBA 327 methods. Overall, comparing synergy scores (Fig 7) , FBA-res and FBA-ko synergy scores 328 shows no consistency with the experimental results, while the FBA-div simulations yield 329 significant positive correlations (R ~ 0.44, p < 0.01) for max(ΔI). Accordingly, FBA-div 330 represents the most accurate computational predictor of serial target anti-metabolic 331 synergies. 332 333 Discussion 334
While FBA methodologies have shown great potential for rationalizing metabolic 335 engineering efforts and identifying synthetic lethal genetic dependencies, traditional FBA 336 knockout simulations fail to predict the most useful antibiotic synergies that target 337 metabolism. As drug combination therapies gain importance for antibiotic treatment, more 338 accurate large-scale prediction methods are sorely in demand. Here we show that 339 extending FBA simulation using flux diversion can accurately model the strong dose-340 dependent synergies observed between inhibitors of bacterial metabolism. 341
The FBA-div methodology outperforms both FBA-res and standard knockout FBA for 342 predicting experimental combination effects, especially for one of the most important 343 antibacterial combinations that target metabolism. Prior approaches for simulating drug 344 epistasis completely missed synergies like sulfamethoxazole and trimethoprim, because 345 knockout and restriction-based approaches find no interactions between serial targets in a 346 pathway. In contrast, FBA-div predicts strong synergies from targeting sequential targets in 347 the same pathway, similar to what has been found for competitive inhibition of serial targets 348 with negative feedback in kinetic simulations [10] . While this is not the usual expectation 349 from paired knockout analyses [18] it is consistent with strong antibiotic synergies being used 350 in the clinic. Among our 28 tested combinations, the correlation between FBA-div and 351 experimental synergy scores is modest (R ~ 0.442), due to the scarcity of selective 352 metabolic inhibitors. However, with metabolism increasingly a focus of drug development, 353 especially for combinations, FBA-div simulations could help discover and prioritize drug 354 targets in multiple disease areas. 355
Broader patterns of synergy across pathways (eg, Fig 3 and S4 Fig) can also provide 356 key insights into the functional connections that are most relevant to the system under 357 study [10, 18] . It is notable that there are consistent patterns of single agent activity and 358 combination epistasis within a pathway, and again consistent patterns between targets 359 across pathways, confirming target connection topology as a major determinant of simulated 360 combination effects [10, 18] . All three methods discussed here find strong synthetic lethality 361 between isozymes of essential reactions, and weaker interactions between alternative 362 essential pathways. However, FBA-div provides by far the richest source of predicted 363 synergies.
For example, the citrate cycle synergizes with Lysine metabolism, but 364 exceptionally strongly with SDPTA, revealing a direct connection through that enzyme's by-365 product alpha-ketoglutarate. Similarly, other connections with amino acid metabolism are 366 revealed for the murein and folate biosynthesis pathways. 367
Differences between the FBA-res and FBA-div methodologies may be understood in 368 FBA models have indeed been augmented with explicit constraints on metabolite and Gibbs 394 free energy levels to more accurately predict global flux distributions [39] . Put in simpler 395 terms, FBA-res cannot predict serial target synergies because mass conservation during 396 optimization requires any flux restriction to apply throughout a serial pathway, forcing the 397 combined effect to match that of the most effective inhibitor. In FBA-div, however, inhibition 398 diverts intermediate reaction flux to waste, yielding greater biomass reductions. 399
The FBA-div approach can be extended to metabolic models of pathogens, such as 400 tuberculosis [40] , plasmodium [41] , and the ESKAPE pathogens [42] . As more FBA models 401 become available for pathogens, combination effects within the current space of drugs and 402 drug-like small molecules could be simulated, and new therapies could be rapidly tested 403 against drug-resistant strains. Indeed, FBA-div for human metabolism is increasingly 404 conceivable as mammalian FBA models[43] become more established. Our FBA-div 405 perturbation approach could also be used with simulation methodologies that extend FBA to 406 transcriptional regulation using ChIP-Seq and gene expression information [44] , enabling yet 407 more realistic simulations of drug effects in biological systems. Finally, flux diversion may 408 also more accurately predict synergies between 3 or more drugs [4, 13, 45] .
These 409 extensions would also enable useful synergy predictions for drug combinations targeting 410 mammalian metabolism. 411
Experimental work on drug combinations can be resource intensive, especially for 412 pathogens which require a BSL 3 environment, or when large combinatorial spaces are 413 comprehensively sampled. Thus, computational tools that can explore large-scale models to 414 prioritize such resource-intensive work could significantly accelerate drug discovery 415 research. Because it can accurately predict a great variety of drug synergies, FBA-div has 416 the potential to make a major impact on these therapeutic challenges. 417 418 419 420 421 422 Figures Fig 1. Simulations of inhibited FBA metabolism. (A) Cartoon of a target enzyme "j" which acts on substrate "i" at a steady-state velocity v j . Other enzymes may compete for the same substrate, and downstream reactions will convert all products to "biomass" flux or unproductive "waste" that is degraded or exported. (B) When the target is knocked out by setting v j =0, substrate backlog increases flow through other reactions, and increased waste rates reduce biomass. (C) FBA-res reduces the target velocity by a scalar factor α, causing a partial knockout effect. (D) For FBA-div, the reaction's affinity is reduced by scaling its stoichiometric coefficient s ij , diverting the backlog to waste. This yields stronger effects than FBA-res, reducing effects on the rest of the network. 424 425
Fig 2. Activity and synergy measures for each combination.
(A) Inhibition of each enzyme was simulated at five α concentrations, using 3-fold dilution intervals centered on the concentration that yielded half of the maximum simulated effect. Note that the 3x dilution steps were constant in simulated concentration α-1, so they are not always equal on these curve plots based on α. The maximum inhibition max(I) and 50% crossing concentration IC50 was measured for each target (IC50 = top concentration if max(I)<0.5), and each combination was simulated at all 25 concentration pairs. (B) For combinations, we scored the maximum effect max(I) and synergy over Gaddum's "best single agent" reference max(ΔI) = max{I XY -max(I X ,I Y )} across all inhibitions I XY . We also calculated "potency shift index" from the 50% inhibition crossing concentrations (C50 X ,C50 Y ) along the matrix diagonal (blue), where SI50 = max(C50 X /IC50 X ,C50 Y /IC50 Y ). Epistasis types for (C) FBA-res and (D) FBA-div simulations on three example target pairs. Interactions were classified based on the single agent and combination effect and synergy, as either noninteracting "None", synthetic lethality "SL" between inactive inhibitors, partial SL "PSL" involving one active agent, or potentiation "Pot" between two active inhibitors. Fig 2) , with enzymes organized by pathway and metabolic reaction order in the iAF1260 model. Symbol shape shows the type of epistasis (synthetic lethal "SL", partial synthetic lethal "PSL", potentiation "Pot", or non-interaction "None"), size shows the effect max(I), and color shows the synergy max(ΔI) between two targets (same scale as We tested 28 combinations of metabolic inhibitors using an E. coli proliferation assay. Synergy score comparison for all combinations, where shape/color shows experimental interaction class, and open symbols indicate epistasis type. We find no agreement (R~0) between the experimentally determined drug interactions and FBA-res. However, experimental and FBA-div synergy are correlated (R~0.44). In addition to the antibiotic combinations, weaker synergy is predicted and observed for other interactions between murein synthesis inhibitors and targets further upstream. 
